Gilead Sciences, Inc. (FRA:GIS)
93.94
-0.50 (-0.53%)
At close: Jun 20, 2025
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B USD in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.30
Revenue / Employee
$1.63M
Employees
17,600
Market Cap
114.43B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Healthineers AG | 23.14B |
Gilead Sciences News
- 5 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD - PRNewsWire
- 7 days ago - FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag - Benzinga
- 8 days ago - FDA approves first twice-yearly injection that prevents HIV infection - Fox News
- 8 days ago - U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects - Fortune
- 8 days ago - AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention - Business Wire
- 8 days ago - Twice-a-year shot to prevent HIV approved in U.S. - CBC News
- 8 days ago - FDA approves 6-month HIV prevention shot - The Hill
- 8 days ago - Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug - Investor's Business Daily